AIEOP-BFM ALL 2009 PDF

Treatment and endpoints. – AIEOP-BFM ALL – AIEOP-BFM ALL • Perspectives. ALL, acute lymphoblastic leukemia; MRD, minimal residual disease. Principal investigator of clinical trial. Pr Martin SCHRAPPE; Klinik für Kinder- und Jugendmedizin I; Universitätsklinikum Schleswig-Holstein – Campus Kiel. Blood ; doi: .. Accordingly, in the AIEOP-BFM ALL study, these 2 groups of patients.

Author: Kagak Vudosho
Country: Saint Kitts and Nevis
Language: English (Spanish)
Genre: Education
Published (Last): 12 August 2007
Pages: 434
PDF File Size: 11.54 Mb
ePub File Size: 2.61 Mb
ISBN: 833-3-23993-955-7
Downloads: 77047
Price: Free* [*Free Regsitration Required]
Uploader: Gogis

Receiver operating characteristic ROC analysis was performed using Medcalc to estimate the best discriminatory thresholds for MRD [15]. National Center for Biotechnology InformationU. The exception was a patient with very unusual MRD kinetics with MRD increasing by more than one log level at both day 33 and day Patients on this trial were stratified into risk groups using MRD levels at day 33 and day 79 and other risk factors [4].

AIEOP-BFM ALL 2009

Aueop-bfm these items you should use the filters and not add them to your search terms in the text field. Anna Kinderkrebsforschung Full Title: Pneumonia AND sponsor name. International, multicenter, randomized clinical trial Phase III. Results The MRD results at day 15 and day 33 were first evaluated by comparing the proportion of patients with low, moderate, high and very high levels of MRD in relapsed and non-relapsed patients Figure 2. Aieop-nfm consent was given for all patients at the hospitals and a copy forwarded to CCIA.

Progress in the treatment of acute lymphoblastic leukaemia in children and adolescents has been made in the last 10 to15 years mainly through refinement of risk stratification and adaptation of chemotherapy. Trials with results Trials without results Clear advanced search filters.

Try This PDF:   ALESIS MASTERLINK MANUAL PDF DOWNLOAD

End of recruitment; Cancer AND drug name. Date study was submitted in EudraCT. Published online Oct Please review our privacy policy. The advanced knowledge about genetics of ALL and molecular regulation of treatment response and resistance represents the basis for the design of contemporary treatment protocols.

Clinical Trials Register

The authors have declared that no competing interests exist. Giles1 Anita Y. The medium risk group were patients not qualifying for either wieop-bfm or high risk. Conceived and designed the experiments: In the case of non-availability of at least two sensitive MRD markers sensitivity at least 10 -4MRD risk group stratification can also be based on only aieop-bvm sensitive marker.

PCR-MRD methodologies are now well established and the development of PCR-MRD assays for each patient by day 33, involving target detection, sequencing and primer design, is no longer a difficult challenge. Male, Female Trial protocol: Aieop-hfm study of the value of day 15 MRD is needed to overcome the limitations inherent in doing a retrospective study on an incomplete set of patient samples.

MRD at day 15 of therapy provided additional predictive value in precursor B-ALL patients treated on this MRD intervention protocol and could be wll in future to identify additional patients at high risk of relapse. The value of MRD at even earlier timepoints in induction day 15 or day 19 in the identification of patients with particularly favourable outcomes has already been established for MRD measured by quantitative flow cytometry [6][7] and in small PCR-MRD studies [8] — [10].

High Risk patients as identified by day 33 – randomized study question: In Table 1the characteristics of the whole group of patients are compared with the 89 patients excluded due to lack of day 15 sample or suitable assay; with the patients included and the 53 included patients who relapsed.

Try This PDF:   THE BACKBENCHERS THE EXTRA CLASS DOWNLOAD

These data collectively suggested that the early MRD timepoints can provide additional prognostic information useful for stratifying patients with precursor B-ALL. Marshall13 Murray D. These effects were not apparent in the 30 T-ALL patients but were maintained in the whole cohort.

It is also important to note that these criteria identified 13 of the 14 precursor B-ALL patients originally stratified as high risk due to high MRD at day Received Jun 25; Accepted Aug The MRD results at day 15 and day 33 were first evaluated by comparing qll proportion of patients with low, moderate, high and very high levels of MRD in relapsed and non-relapsed patients Figure 2.

This will provide an RSS feed alp clinical trials matching your search that have been added or updated in the last 7 days. Standard risk and medium risk patients were treated uniformly according to the common control arm in BFM ALL and high risk patients were assigned to treatment with novel high risk chemotherapy blocks [4].

No results available EudraCT Number: Pediatr Blood Cancer